Chronic kidney disease (CKD) refers to a variety of different diseases characterized by impairment of kidney structure and/or renal function. The prevalence of CKD in China is as high as 10.8%. With a population of more than 150 million, China has the largest number of CKD patients all over the world. People with CKD would not only progress to uremia and need renal replace treatment, it also significantly increases risk of cardiovascular disease than non-CKD population. It has created a heavy burden on people's health and national economy. There is an urgent need to establish an effective system for CKD prevention and control in China. Evidences from large sample cohort and real world based research are still rare. This study will provide good experience for reducing the occurrence and development of CKD.
Patients diagnosed with CKD as defined in the KDIGO Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease 2012 Edition;
Non-CKD patients with hypertension, diabetes, hyperlipidemia, hyperuricemia, eGFR (CKD-EPI formula) of 60-89 ml/min/1.73m² and other risk factors for CKD;
Healthy population.
Signed the informed consent voluntarily.
None
Enrolled based on both hospitals and communities.
Cohort
Prospective
Not listed
The occurrence of chronic kidney diseases in non-CKD participants
The occurrence of chronic kidney disease is defined by KDIGO (Kidney Disease: Improving Global Outcomes) in 2012.
The progression of chronic kidney diseases in CKD participants
The progression of chronic kidney disease is defined as: Patients with baseline estimated glomerular filtration rate (eGFR) ≥60 ml /min/1.73m2 had an eGFR decrease of 30% or more, and decreased to \<60 ml /min/1.73m2; Or a 50% or greater decrease in baseline eGFR \<60 ml /min/1.73m2; Or end-stage renal disease (eGFR \<15 ml /min/1.73m2, or initiation of renal replacement therapy)
Progression in albuminuria
Progression in albuminuria: Patients with baseline urinary albumin to creatinine Ratio (uACR) \<30 mg/g had uACR doubled and increased to ≥30 mg/g; or patients with baseline uACR \<300 mg/g had a doubling of uACR and an increase to ≥300 mg/g.
New onset of albuminuria
Onset of albuminuria: Patients with baseline uACR \<30 mg/g increased to ≥30 mg/g.
New onset of macroalbuminuria
Onset of macroalbuminuria: Patients with baseline uACR \<300 mg/g increased to ≥300 mg/g.
Composite endpoints of progression of chronic kidney disease and progression of albuminuria
Composite endpoints of progression of chronic kidney disease and progression of albuminuria.
The occurrence and development of complications of chronic renal disease
Renal anemia, renal hypertension, mineral bone metabolism disorders, etc.
Rate of Participants with cardiovascular events.
Rate of Participants with cardiovascular events.
Rate of Participants with cerebrovascular events.
Rate of Participants with cerebrovascular events.
All causes mortality
All causes mortality.
Click on the lead sponsor to view all of their trials.
